Molecular monitoring in endometrial cancer - ready for prime time?

Efforts are underway to define the role of minimally invasive strategies for molecular monitoring and risk stratification in endometrial cancer (EC). A recent publication aims to define the association between circulating tumour DNA (ctDNA) level and disease stage in newly diagnosed EC patients and determine whether sequencing of longitudinal cell-free DNA (cfDNA) samples can be used for disease monitoring and detection of progression or recurrence. These results accelerate the current knowledge of molecular follow up in EC.